Prognostic and Diagnostic Value of ProBNP in Iranian Patients With Chest Pain at a Tertiary Cardiovascular Center

Document Type : Original Article

Authors

1 Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.

2 Cardiogenetics Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.

3 Rajaie Cardiovascular Medical and Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, IR Iran.

Abstract

Background: Diagnosis and early treatment of the cardiac causes of chest pain are of particular importance. This study aimed to investigate the association between NT-pro-BNP levels as a cardiac marker and the prognosis of patients with chest pain.
Methods: All patients visiting the emergency department of a tertiary cardiovascular center with chest pain between October 2016 and March 2017 were evaluated for eligibility. Demographic data, proBNP levels, final diagnosis on angiography, echocardiography, and other symptoms were recorded.
Results: A total of 222 patients at a mean age of 59.0±14.8 years were studied. Totally, 127 patients (57.2%) were male. A significant inverse relationship was found between proBNP levels and the left ventricular ejection fraction (r= -0.316; P<0.001). NT-proBNP levels showed a significant elevation in patients with abnormal size and function of the right ventricle, with regional wall motion abnormalities, and with valvular heart diseases (P<0.05). The BNP level in patients with abnormal angiographic results was 1148.5 (405.3–3214.0), significantly higher than that in patients with normal results (545.0: 90.3–2807.8; P=0.009). The level of this marker in patients with obstructive coronary artery disease (1192.0: 438.8–3233.0) was significantly higher than that in patients with non-obstructive coronary artery disease (620.0: 108.0–2792.0; P=0.001). BNP>841 pg/mL had a sensitivity of 92.9% and a specificity of 47.9% in identifying cases at risk of complications.
Conclusions: NT-proBNP could be a good diagnostic and prognostic marker for patients with chest pain complaints. Measuring this marker upon arrival can help identify patients with cardiac diseases. It is recommended to evaluate patients with elevated levels of this marker for earlier diagnosis and treatment. (Iranian Heart Journal 2023; 24(2): 23-34)

Keywords

References

  1. Salehi Omran M.T. AM. Evaluation of Coronary Artery Disease in Patients with Atypical Chest Pain Based on Exercise Test. Journal of Babol University of Medical Sciences. 2017; 19(1):43-7.
  2. Leistner DM, Klotsche J, Palm S, Pieper L, Stalla GK, Lehnert H, et al. Prognostic value of reported chest pain for cardiovascular risk stratification in primary care. European journal of preventive cardiology. 2014; 21(6):727-38.
  3. Mann D, Zipes D, Libby P, Bonow R. Braunwald's Heart Disease. 10th ed. Philadelphia: Philadelphia; 2015.
  4. Mann D, Zipes D, P. L, Bonow R. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 10 th ed. Philadelphia: Saunders; 2014.
  5. Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson J, et al. Harrison's principle of internal medicine. 17 th ed. New York: McGraw-Hill Professional; 2008.
  6. Jafari H, Shafipour V, Ghaemian A, Rastgarnia N, Mohammadpour RA, Esmaeili R, et al. The relation between BMI with exercise test in individuals with cardiac ischemic pains. Journal of Mazandaran University of Medical Sciences. 2009; 18(68):64-9.
  7. Fodor JG, Tzerovska R. Coronary heart disease: is gender important? The journal of men's health & gender. 2004; 1(1):32-7.
  8. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC, Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002; 40(5):976-82.
  9. Daniels L, Maisel A. Natriuretic peptides. J Am Coll Cardiol 2007; 18(50):2357-69.
  10. Stewart R. Broader indications for B-type natriuretic peptide testing in coronary artery disease. Eur Heart J. 2005; 26(3):207-9.
  11. Marx A, Hackbeger J, Walls C, editors. Rosen emergency medicine; concepts and clinical practice. 6th ed ed. Philadelphia: Mosby Elsevier 2006.
  12. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart. 2003; 89(7):745-51.
  13. Yang Y, Li C, Zhao L. Association of B-type natriuretic peptide with coronary plaque subtypes detected by coronary computed tomography angiography in patients with stable chest pain. The international journal of cardiovascular imaging. 2017; 33(10):1599-606.
  14. Kotecha D, Flather MD, Atar D, Collins P, Pepper J, Jenkins E, et al. B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease. BMC Medicine. 2019; 17(1):72.
  15. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. The New England journal of medicine. 2004; 350(7):647-54.
  16. Christ M, Thuerlimann A, Laule K, Klima T, Hochholzer W, Perruchoud AP, et al. Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. European journal of clinical investigation. 2007; 37(11):834-41.
  17. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet (London, England). 1994; 343(8895):440-4.
  18. Takeuchi H, Sata M. The relationship among brain natriuretic peptide (BNP), cholesterol and lipoprotein. Heart Asia. 2012; 4(1):11-5.
  19. He W-T, Mori M, Yu X-F, Kanda T. Higher BNP levels within physiological range correlate with beneficial nonfasting lipid profiles in the elderly: a cross-sectional study. Lipids Health Dis. 2016; 15:3-.
  20. van Wezenbeek J, Canada JM, Ravindra K, Carbone S, Trankle CR, Kadariya D, et al. C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction. Frontiers in Cardiovascular Medicine. 2018; 5(178).
  21. Blyth KG, Groenning BA, Mark PB, Martin TN, Foster JE, Steedman T, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. European Respiratory Journal. 2007; 29(4):737.
  22. Cao Z-P, Xue J-J, Zhang Y, Tian M-H, Xiao Y, Jia Y-Q, et al. Differential expression of B-type natriuretic peptide between left and right ventricles, with particular regard to sudden cardiac death. Mol Med Rep. 2017; 16(4):4763-9.
  23. Krüger S, Graf J, Merx MW, Koch KC, Kunz D, Hanrath P, et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. American heart journal. 2004; 147(1):60-5.
  24. Azevedo JC, Reis BC, Barreto NM, DS FJ, Prezotti LS, Procaci VR, et al. BNP was associated with ischemic myocardial scintigraphy and death in patients at chest pain unit. Arquivos brasileiros de cardiologia. 2015; 104(1):16-23.
  25. Palazzuoli A, Beltrami M, Ruocco G, Franci B, Campagna MS, Nuti R. Diagnostic utility of contemporary echo and BNP assessment in patients with acute heart failure during early hospitalization. European journal of internal medicine. 2016; 30:43-8.
  26. Hasumi E, Iwata H, Kohro T, Ando J, Sawaki D, Takahashi M, et al. Abstract 17669: Change in Levels Of B-Type Natriuretic Peptide (BNP) During Follow up Predicts in Stent Restenosis After Drug-Eluting Stent (DES) Implantation. Circulation. 2010;122(suppl_21):A17669-A.
  27. Hasumi E, Iwata H, Kohro T, Manabe I, Kinugawa K, Morisaki N, et al. Diagnostic implication of change in b-type natriuretic peptide (BNP) for prediction of subsequent target lesion revascularization following silorimus-eluting stent deployment. International journal of cardiology. 2013; 168(2):1429-34.
  28. Hong SN, Ahn Y, Yoon NS, Lee KH, Kim YS, Hwang SH, et al. Usefulness of serum N-terminal pro-brain natriuretic peptide to predict in-stent restenosis in patients with preserved left ventricular function and normal troponin I levels. The American journal of cardiology. 2007; 99(8):1051-4.
  29. Kawabe M, Sato A, Hoshi T, Endo M, Yoshida I, Aonuma K. Incremental value of B-type natriuretic peptide for detection and risk reclassification of obstructive coronary artery disease on computed tomography angiography. Journal of Cardiology. 2017; 69(4):671-7.
Iranian Heart Journal
Volume 24, Issue 2
April 2023
Pages 23-34

Files

Share

How to cite

Statistics